Table 2 Characteristics of included studies.
Impact factor (categorized) | All studies (n = 216) | Studies with switching (n = 39) | Studies without switching (n = 177) |
|---|---|---|---|
Number (%) | Number (%) | Number (%) | |
High (>25) | 20 (9) | 3 (8) | 17 (10) |
Intermediate (≥15 ≤ 25) | 72 (33) | 16 (41) | 56 (32) |
Low (<15) | 124 (57) | 20 (51) | 104 (59) |
Sex | |||
Male | 165 (76) | 34 (87) | 131 (74) |
Female | 51 (24) | 5 (13) | 46 (26) |
Funding | |||
For-profit | 112 (52) | 11 (28) | 101 (57) |
Mixed | 49 (23) | 12 (31) | 37 (21) |
Non-profit | 41 (19) | 9 (23) | 32 (18) |
NA | 14 (6) | 7 (18) | 7 (4) |
Conflict of Interest | |||
Yes | 142 (66) | 22 (56) | 120 (68) |
No | 63 (29) | 12 (31) | 51 (29) |
NA | 11 (5%) | 5 (13) | 6 (3) |
Control group | |||
Active | 172 (80) | 31 (80) | 141 (80) |
Placebo | 34 (16) | 4 (10) | 30 (17) |
Observation | 10 (4) | 4 (10) | 6 (3) |
Type of primary surrogate outcome in published manuscript | |||
Complete response/Overall response/Response rate | 48 (22) | 7 (18) | 41 (23) |
Progression free survival | 101 (47) | 13 (33) | 88 (50) |
Other | 67 (31) | 19 (49) | 48 (27) |
Population | Median (IQR) | Median (IQR) | Median (IQR) |
Patients | 171 (90–409) | 159 (80–452) | 173 (95–396) |
